|
1.
|
Mathis D, Vence L and Benoist C: beta-Cell
death during progression to diabetes. Nature. 414:792–798. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Butcher EC and Picker LJ: Lymphocyte
homing and homeostasis. Science. 272:60–66. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Nandi A, Estess P and Siegelman M:
Bimolecular complex between rolling and firm adhesion receptors
required for cell arrest; CD44 association with VLA-4 in T cell
extravasation. Immunity. 20:455–465. 2004. View Article : Google Scholar
|
|
4.
|
Weber C: Novel mechanistic concepts for
the control of leukocyte transmigration: specialization of
integrins, chemokines, and junctional molecules. J Mol Med (Berl).
81:4–19. 2003.
|
|
5.
|
Seiki M: Membrane-type 1 matrix
metalloproteinase: a key enzyme for tumor invasion. Cancer Lett.
194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Savinov AY, Rozanov DV, Golubkov VS, Wong
FS and Strongin AY: Inhibition of membrane type-1 matrix
metalloproteinase by cancer drugs interferes with the homing of
diabetogenic T cells into the pancreas. J Biol Chem.
280:27755–27758. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Suenaga N, Mori H, Itoh Y and Seiki M:
CD44 binding through the hemopexin-like domain is critical for its
shedding by membrane-type 1 matrix metalloproteinase. Oncogene.
24:859–868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kajita M, Itoh Y, Chiba T, et al:
Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes
cell migration. J Cell Biol. 153:893–904. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Savinov AY, Rozanov DV and Strongin AY:
Mechanistic insights into targeting T cell membrane proteinase to
promote islet beta-cell rejuvenation in type 1 diabetes. FASEB J.
20:1793–1801. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cappuzzo F, Bartolini S and Crinó L:
Emerging drugs for non-small cell lung cancer. Expert Opin Emerg
Drugs. 8:179–192. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ikejiri M, Bernardo MM, Bonfil RD, et al:
Potent mechanism-based inhibitors for matrix metalloproteinases. J
Biol Chem. 280:33992–34002. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Rosenblum G, Meroueh SO, Kleifeld O, et
al: Structural basis for potent slow binding inhibition of human
matrix metalloproteinase-2 (MMP-2). J Biol Chem. 278:27009–27015.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Annabi B, Lachambre MP, Bousquet-Gagnon N,
Page M, Gingras D and Beliveau R: Green tea polyphenol
(−)-epigallocatechin 3-gallate inhibits MMP-2 secretion and
MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys
Acta. 1542:209–220. 2002.
|
|
14.
|
Cheng XW, Kuzuya M, Kanda S, et al:
Epigallocatechin-3-gallate binding to MMP-2 inhibits gelatinolytic
activity without influencing the attachment to extracellular matrix
proteins but enhances MMP-2 binding to TIMP-2. Arch Biochem
Biophys. 415:126–132. 2003. View Article : Google Scholar
|
|
15.
|
Cheng XW, Kuzuya M, Nakamura K, et al:
Mechanisms of the inhibitory effect of epigallocatechin-3-gallate
on cultured human vascular smooth muscle cell invasion.
Arterioscler Thromb Vasc Biol. 25:1864–1870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dell’Aica I, Donà M, Sartor L, Pezzato E
and Garbisa S: (−)Epigallocatechin-3-gallate directly inhibits
MT1-MMP activity, leading to accumulation of nonactivated MMP-2 at
the cell surface. Lab Invest. 82:1685–1693. 2002.
|
|
17.
|
Demeule M, Brossard M, Pagé M, Gingras D
and Béliveau R: Matrix metalloproteinase inhibition by green tea
catechins. Biochim Biophys Acta. 1478:51–60. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yamakawa S, Asai T, Uchida T, Matsukawa M,
Akizawa T and Oku N: (−)-Epigallocatechin gallate inhibits
membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor
angiogenesis. Cancer Lett. 210:47–55. 2004.
|
|
19.
|
Savinov AY, Wong FS, Stonebraker AC and
Chervonsky AV: Presentation of antigen by endothelial cells and
chemoattraction are required for homing of insulin-specific
CD8+ T cells. J Exp Med. 197:643–656. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wong FS, Visintin I, Wen L, Flavell RA and
Janeway CA Jr: CD8 T cell clones from young nonobese diabetic (NOD)
islets can transfer rapid onset of diabetes in NOD mice in the
absence of CD4 cells. J Exp Med. 183:67–76. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Strongin AY, Collier I, Bannikov G, Marmer
BL, Grant GA and Goldberg GI: Mechanism of cell surface activation
of 72-kDa type IV collagenase. Isolation of the activated form of
the membrane metalloprotease. J Biol Chem. 270:5331–5338. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Strongin AY, Marmer BL, Grant GA and
Goldberg GI: Plasma membrane-dependent activation of the 72-kDa
type IV collagenase is prevented by complex formation with TIMP-2.
J Biol Chem. 268:14033–14039. 1993.PubMed/NCBI
|
|
23.
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Li W, Savinov AY, Rozanov DV, et al:
Matrix metalloproteinase-26 is associated with estrogen-dependent
malignancies and targets alpha1-antitrypsin serpin. Cancer Res.
64:8657–8665. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Mast AE, Enghild JJ, Nagase H, Suzuki K,
Pizzo SV and Salvesen G: Kinetics and physiologic relevance of the
inactivation of alpha 1-proteinase inhibitor, alpha
1-antichymotrypsin, and antithrombin III by matrix
metalloproteinases-1 (tissue collagenase), -2 (72-kDa
gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem.
266:15810–15816. 1991.
|
|
26.
|
Strongin AY: Mislocalization and
unconventional functions of cellular MMPs in cancer. Cancer
Metastasis Rev. 25:87–98. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zhou YP, Madjidi A, Wilson ME, et al:
Matrix metalloproteinases contribute to insulin insufficiency in
Zucker diabetic fatty rats. Diabetes. 54:2612–2619. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
O’Brien PM, Ortwine DF, Pavlovsky AG, et
al: Structure-activity relationships and pharmacokinetic analysis
for a series of potent, systemically available biphenylsulfonamide
matrix metalloproteinase inhibitors. J Med Chem. 43:156–166.
2000.
|
|
29.
|
Peterson JT, Hallak H, Johnson L, et al:
Matrix metalloproteinase inhibition attenuates left ventricular
remodeling and dysfunction in a rat model of progressive heart
failure. Circulation. 103:2303–2309. 2001. View Article : Google Scholar
|
|
30.
|
Savinov AY and Strongin AY: Matrix
metalloproteinases, T cell homing and beta-cell mass in type 1
diabetes. Vitam Horm. 80:541–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Chong AS, Shen J, Tao J, et al: Reversal
of diabetes in non-obese diabetic mice without spleen cell-derived
beta cell regeneration. Science. 311:1774–1775. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Suri A, Calderon B, Esparza TJ, Frederick
K, Bittner P and Unanue ER: Immunological reversal of autoimmune
diabetes without hematopoietic replacement of beta cells. Science.
311:1778–1780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Nishio J, Gaglia JL, Turvey SE, Campbell
C, Benoist C and Mathis D: Islet recovery and reversal of murine
type 1 diabetes in the absence of any infused spleen cell
contribution. Science. 311:1775–1778. 2006. View Article : Google Scholar : PubMed/NCBI
|
